News

Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

Expansion of leadership team to strengthen global clinical expertiseBRISBANE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq:…

1 year ago

Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan’s AI Generated Biomarker Data Changes Surgical Treatment Plans

Surgeons Will Determine Their Surgical Treatment Plan Before Nociscan and Report on How Often the Surgical Plan Changes After Receiving…

1 year ago

Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Aug. 21,…

1 year ago

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…

1 year ago

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company…

1 year ago

PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy

Designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better…

1 year ago

CTT Pharmaceuticals Holdings, Inc. Successfully Completes 2 Year PCAOB Audit

TAMPA, Fla., Aug. 21, 2024 (GLOBE NEWSWIRE) -- CTT Pharmaceuticals Holdings, Inc. (OTC: CTTH), is pleased to announce that the…

1 year ago

NewGenIvf Announces Filing of 2023 Annual Report with the SEC

Total Revenues Reach US$5.1 MillionGross Profit Increases by 9.4% to US$1.7 MillionNet Income of US$0.1 million BANGKOK, Thailand, Aug. 21,…

1 year ago

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

Patented personalized medicine approach for patient dosing for autologous cell therapyExpected to meaningfully enhance clinical experience and market opportunity SUNNYVALE,…

1 year ago

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

──Reported Positive Phase 2 Results Demonstrating Safety and Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC)── ──Establishes…

1 year ago